A New Stochastic Model for Subgenomic Hepatitis C Virus Replication Considers Drug Resistant Mutants

Nikita V. Ivanisenko, E. L. Mishchenko, Ilya R. Akberdin, П. С. Деменков, В. А. Лихошвай, Konstantin Kozlov, Dmitry Todorov, Vitaly V. Gursky, M. G. Samsonova, A. M. Samsonov, Diana Clausznitzer, Lars Kaderali, Н. А. Колчанов, В. А. ИванисенкоPLoS 2014 · DOI

Abstract

Hepatitis C virus (HCV) rapidly acquires drug resistance, complicating the design of effective antivirals. We developed a stochastic model of subgenomic HCV replicon replication that accounts for the emergence and selection of drug-resistant mutants. By incorporating key NS3 protease mutations (A156T, D168V, R155Q, etc.) resistant to inhibitors like BILN-2061 and VX-950, the model describes long-term viral RNA suppression dynamics. Our results suggest that pre-existing mutants contribute significantly to resistance during treatment, and observed kinetic differences across inhibitor concentrations stem from variations in mutant replication rates and drug sensitivities.

Introduction: The Challenge of Viral Adaptation

Hepatitis C is a master of adaptation. Its replication machinery, the NS5B polymerase, lacks a proofreading function, leading to an exceptionally high mutation rate. This results in a "quasispecies" population—a diverse cloud of genetic variants within a single host. When Direct-Acting Antivirals (DAAs) such as protease inhibitors are introduced, the dominant "wild-type" virus is suppressed, but rare, drug-resistant mutants can rapidly proliferate.

Traditional deterministic models, which rely on population averages, often fail to capture the "noisy," random events occurring at low viral concentrations—precisely when a single resistant mutant might determine therapeutic success. This research bridges that gap using a stochastic approach to simulate individual molecular interactions.

Methods: A Stochastic Framework for Replication

The researchers constructed a stochastic mathematical model of the HCV subgenomic replicon, a laboratory tool that replicates without infecting new cells.

The Gillespie Algorithm

To manage the randomness of low-concentration molecular events, the model employs the Gillespie Algorithm's "Next Step" method. This allows the simulation to track discrete events, such as the translation of a single polyprotein or the formation of an individual replication vesicle.

Biological Integration

The model tracks the complete intracellular cycle: IRES-mediated translation, polyprotein processing by the NS3 protease, the formation of membrane-bound replication vesicles, and the synthesis of new RNA strands.

Schematic representation of the stochastic model for HCV replication, including wild-type and mutant pathways.

Key mutations in the NS3 protease (e.g., A156T, D168V, R155Q) known to confer resistance to early-generation inhibitors like Telaprevir and Boceprevir were explicitly incorporated. The model was calibrated using the DEEP (Differential Evolution Entirely Parallel) optimization technique against experimental datasets for BILN-2061, VX-950, and SCH-503034.

Key Insights and Results

The stochastic model provided several critical insights into the dynamics of drug resistance:

  • Pre-existing Mutants: The model confirms that resistance is rarely "invented" during treatment. Instead, resistant mutants typically pre-exist at low levels (approx. 1%). Treatment acts as a selective filter, removing the wild-type and allowing these mutants to flourish.
  • Biphasic Decline: Viral RNA levels typically show a sharp initial drop (Phase 1) followed by a slower decline or rebound (Phase 2). The model identifies Phase 1 as the clearance of the wild-type virus and Phase 2 as the growth of drug-resistant mutants.
  • Fitness Trade-offs: Many drug-resistant mutants exhibit a "fitness cost," replicating slower than the wild-type in the absence of inhibitors. The model quantifies these trade-offs to predict which mutants will dominate at specific drug concentrations.
Simulated long-term dynamics of viral RNA for various NS3 protease mutants, showing differences in replication capacity.
  • Long-term Predictive Power: Unlike previous deterministic models that lost accuracy after 72 hours, this stochastic approach accurately simulated viral dynamics over 9 to 15 days. It successfully predicted the dominance of resistant species as early as 5 days into monotherapy.

Conclusion and Future Directions

This model serves as a robust tool for interpreting anti-HCV drug tests and predicting the efficacy of potential therapies. While it currently treats vesicle RNA synthesis as a simplified "black box" rate constant and does not fully account for the host's innate interferon response, future iterations aim to include multi-drug "cocktails" and more detailed cellular immune interactions. Such advancements will better reflect modern clinical regimens and help optimize treatment strategies against highly mutable viruses.

Summary updated

Abstract

As an RNA virus, hepatitis C virus (HCV) is able to rapidly acquire drug resistance, and for this reason the design of effective anti-HCV drugs is a real challenge. The HCV subgenomic replicon-containing cells are widely used for experimental studies of the HCV genome replication mechanisms, for drug testing in vitro and in studies of HCV drug resistance. The NS3/4A protease is essential for virus replication and, therefore, it is one of the most attractive targets for developing specific antiviral agents against HCV. We have developed a stochastic model of subgenomic HCV replicon replication, in which the emergence and selection of drug resistant mutant viral RNAs in replicon cells is taken into account. Incorporation into the model of key NS3 protease mutations leading to resistance to BILN-2061 (A156T, D168V, R155Q), VX-950 (A156S, A156T, T54A) and SCH 503034 (A156T, A156S, T54A) inhibitors allows us to describe the long term dynamics of the viral RNA suppression for various inhibitor concentrations. We theoretically showed that the observable difference between the viral RNA kinetics for different inhibitor concentrations can be explained by differences in the replication rate and inhibitor sensitivity of the mutant RNAs. The pre-existing mutants of the NS3 protease contribute more significantly to appearance of new resistant mutants during treatment with inhibitors than wild-type replicon. The model can be used to interpret the results of anti-HCV drug testing on replicon systems, as well as to estimate the efficacy of potential drugs and predict optimal schemes of their usage.
BibTeX
@inproceedings{ivanisenko2014new,
  author = {Nikita V. Ivanisenko and E. L. Mishchenko and Ilya R. Akberdin and П. С. Деменков and В. А. Лихошвай and Konstantin Kozlov and Dmitry Todorov and Vitaly V. Gursky and M. G. Samsonova and A. M. Samsonov and Diana Clausznitzer and Lars Kaderali and Н. А. Колчанов and В. А. Иванисенко},
  title = {{A New Stochastic Model for Subgenomic Hepatitis C Virus Replication Considers Drug Resistant Mutants}},
  booktitle = {PLoS},
  year = {2014},
  doi = {10.1371/journal.pone.0091502},
}
Figure